EUCOPE welcomes the European Commission's targeted revision of the Medical Devices Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR), recognising it as a timely opportunity to improve predictability, reduce unnecessary regulatory burdens, and strengthen Europe's competitiveness.
ECP
European Confederation of Pharmaceutical Entrepreneurs (EUCOPE)
Industry association · Belgium · EU Transparency Register 87600691525-93
9
positions filed
in the 326 files tracked
7
legislative files
of 326 tracked
7
with a full position paper
attached to a submission
Counts here are a floor, never a total: they cover the 326 consultation files tracked so far (29,503 submissions, mostly 2025–26), so an organization's real filing history is larger, not smaller.
Who they are
Among the 1205 trade and business associations on this site, they rank #199 by legislative files engaged — a count of participation, not a measure of influence.
4.4
declared lobbying FTE
self-declared
€800K+
declared costs / yr (floor)
10
EP accreditations
as declared to the register
2009
in the register since
Declares membership of
- Kangaroo group
- European Policy Centre →
- Healthcare Chain Institute
Self-declared to the EU Transparency Register (snapshot 30 Aug 2026).
- Register category
- Trade and business associations
- Registered as
- European Confederation of Pharmaceutical Entrepreneurs (EUCOPE)
- Head office
- Brussels, Belgium
Self-declared to the EU Transparency Register (snapshot 30 Aug 2026); cost bands are floors, not audited totals. Reused under Commission Decision 2011/833/EU.
Track European in PolicySpeak: request access →
Work at European Confederation of Pharmaceutical Entrepreneurs (EUCOPE)? so we know who speaks for it.
Their record over time
European Confederation of Pharmaceutical Entrepreneurs (EUCOPE) filed 9 positions between 11 Jun 2025 and 28 Jul 2026, across 7 of the 326 legislative files tracked here, attaching a full position paper 7 times.
2025 · 4 filed2026 · 5 filed
What they argued
The European Confederation of Pharmaceutical Entrepreneurs (EUCOPE) represents small to mid-sized innovative companies in pharmaceuticals, biotechnology, and medical technologies across Europe. EUCOPE welcomes the European Commissions initiative to revise the MDR and IVDR to ensure a more predictable, proportionate, and innovation-friendly framework.
The European Confederation of Pharmaceutical Entrepreneurs (EUCOPE), representing predominantly small- and mid-sized innovative pharmaceutical companies, views Part I of the European Commissions proposed European Biotech Act as a timely and promising initiative.
The European Confederation of Pharmaceutical Entrepreneurs (EUCOPE) supports the European Commissions initiative to develop a Biotech Act and its overarching objective to reinforce the biopharmaceutical research and innovation ecosystem, allowing companies to thrive in the EU.
The European Biotech Act Part I contains several welcome healthcare policy measures. To fully realise its objectives, EUCOPE has identified a set of additional recommendations for the Biotech Act Part II: Reframe biopharmaceutical spending as strategic investments; Promote uptake of biotechnology; Enhance biomanufacturing cooperation with international partners; Scale-up genome sequencing capability and newborn…
The European Confederation of Pharmaceutical Entrepreneurs (EUCOPE) supports the European Commissions initiative to develop a European Innovation Act, and its overarching objective to reinforce the EUs innovation ecosystem and close the innovation gap with its global competitors.
The European Confederation of Pharmaceutical Entrepreneurs (EUCOPE) is the voice of small to mid-sized innovative companies active in the field of pharmaceuticals, biotechnologies and medical technologies at the European level.
The European Confederation of Pharmaceutical Entrepreneurs (EUCOPE) represents small and mid-sized innovative companies in the pharmaceutical, biotechnology and medical technology sectors across Europe. EUCOPE welcomes the opportunity to comment on the draft implementing regulation setting out minimum metadata elements and their characteristics for dataset descriptions required from health data holders under Article…
The European Confederation of Pharmaceutical Entrepreneurs (EUCOPE), representing predominantly small to mid-sized innovative pharmaceutical companies, backs the European Commissions initiative to create a small mid-caps (SMC) category, as established by its Recommendation on the definition of small mid-caps.
Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.
Turns up on the same files
Organizations that also filed on at least two of the same consultations. A shared interest in the same dossiers — not evidence of coordination, and we do not suggest any.
- EFPIA · 6 files in common
- IDEE ECONOMICHE www.idee-economiche.it · 5 files in common
- MedTech Europe · 5 files in common
- EuropaBio · 4 files in common
- Bayer AG · 4 files in common
Showing 5 of 162.
Is this your organization?
Everything on this page comes from European Confederation of Pharmaceutical Entrepreneurs (EUCOPE)’s own submissions to the European Commission — we have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.
Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.